P1, N=30, Active, not recruiting, Tachyon Therapeutics, Inc. | Recruiting --> Active, not recruiting | N=70 --> 30

P1, N=70, Recruiting, Tachyon Therapeutics, Inc. | Phase classification: P1a/1b --> P1

A reduction in the population of tumor-initiating cells was observed following TACH101 treatment. Overall, these observations demonstrate the broad applicability of TACH101 as a potential anticancer agent and support its advancement into clinical trials.

P1a/1b, N=70, Recruiting, Tachyon Therapeutics, Inc. | Not yet recruiting --> Recruiting | Trial completion date: Mar 2024 --> Jul 2025 | Trial primary completion date: Jul 2023 --> Jul 2025

P1a/1b, N=70, Not yet recruiting, Tachyon Therapeutics, Inc. | Phase classification: P1 --> P1a/1b | Trial primary completion date: Nov 2023 --> Jul 2023

Combining KDM4 inhibition with cytotoxic chemotherapy led to tumor regression in preclinical PAX3-FOXO1 RMS subcutaneous xenograft models. In summary, we identified a targetable mechanism required for maintenance of the PAX3-FOXO1-related transcription factor network, which may translate to a therapeutic approach for fusion-positive RMS.

Depletion of KDM4s activated the apoptosis signaling pathway by suppressing MDM2 expression via modulating H3K9me3 levels on the MDM2 promoter region. Our study demonstrates a unique KDM4 inhibitor for LSCs to overcome the resistance to traditional treatment and offers KDM4 inhibition as a promising strategy for resistant leukemia therapy.

These results suggest that myricetin is a pan-KDM4 inhibitor and exhibited potent cell cytotoxicity toward CRPC cells. Importantly, the combination of PLGA-encapsulated myricetin with enzalutamide is potentially effective for CRPC.

Physical binding of KDM4E to Bim and CHOP promoters decreased the response to ML324. Our findings suggest that KDM4 inhibition is a potent anti-tumor therapeutic strategy for human HCC, and further studies of UPR-induced apoptosis and the associated epigenetic functional mechanisms may lead to the discovery of novel target for future cancer therapy.

Furthermore, we provide evidence that the inhibitor's cytostatic properties arise from direct intracellular inhibition of KDM4 enzymes. PCa cells treated with the inhibitor exhibit reduced expression of genes regulated by the androgen receptor, an outcome accompanied by epigenetic maintenance of a heterochromatic state.

P1, N=70, Not yet recruiting, Tachyon Therapeutics, Inc.